Gemcitabine and Ototoxicity - a phase IV clinical study of FDA data

Summary:

Ototoxicity is reported as a side effect among people who take Gemcitabine (gemcitabine), especially for people who are male, 50-59 old, have been taking the drug for 1 - 6 months also take Cisplatin, and have Non-hodgkin's lymphoma.

The phase IV clinical study analyzes which people have Ototoxicity when taking Gemcitabine. It is created by eHealthMe based on reports of 31,291 people who have side effects when taking Gemcitabine from the FDA, and is updated regularly.

What is Gemcitabine?

Gemcitabine has active ingredients of gemcitabine. eHealthMe is studying from 31,337 Gemcitabine users. Check the latest studies of Gemcitabine.

What is Ototoxicity?

Ototoxicity (damage to the ear) is found to be associated with 147 drugs and 357 conditions by eHealthMe. Check the latest studies of Ototoxicity.

On Aug, 03, 2026

31,291 people reported to have side effects when taking Gemcitabine.
Among them, 33 people (0.11%) have Ototoxicity.

Among these 33 people:

How long have people been on Gemcitabine when they have Ototoxicity? *

What is the gender of people who have Ototoxicity when taking Gemcitabine? *

female: 30.77 %
male: 69.23 %

What is the age of people who have Ototoxicity when taking Gemcitabine? *

What are other drugs people take besides Gemcitabine? *

What are other side effects people have besides Ototoxicity? *

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 10 people, 30.30%
Dizziness: 10 people, 30.30%
Disease Progression: 7 people, 21.21%
Renal Impairment (severely reduced kidney function): 6 people, 18.18%
Tinnitus (a ringing in the ears): 5 people, 15.15%
Colitis (inflammation of colon): 5 people, 15.15%
Acute Kidney Failure: 4 people, 12.12%
Neuropathy Peripheral (surface nerve damage): 4 people, 12.12%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 3 people, 9.09%
Bladder Pain: 3 people, 9.09%

What are the existing conditions these people have? *

Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 9 people, 27.27%
Non-Renal Cell Carcinoma Of Kidney (cancer of kidney without involvement of renal cell): 5 people, 15.15%
Cholangiocarcinoma (a cancer that forms glands or secretes significant amounts of mucins): 4 people, 12.12%
Pancreatic Carcinoma (pancreatic cancer): 3 people, 9.09%
Pain: 3 people, 9.09%
Neoplasm Progression (growth of tumour): 1 person, 3.03%
Neoplasm Malignant (cancer tumour): 1 person, 3.03%
Nasal Sinus Cancer (cancer of hollow cavity behind nose): 1 person, 3.03%
Metastases To Lung (cancer spreads to lung): 1 person, 3.03%
Metastases To Liver (cancer spreads to liver): 1 person, 3.03%

* Approximation only. Some reports may have incomplete information.

Do you take Gemcitabine and have Ototoxicity?

- Check whether Ototoxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gemcitabine:

Gemcitabine (31,337 reports)

Ototoxicity treatments and more:

Ototoxicity (1,966 reports)

Browse all side effects of Gemcitabine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Ototoxicity:

Ototoxicity (147 drugs)

Browse all the conditions that are associated with Ototoxicity:

Ototoxicity (357 conditions)

Related publications that referenced our studies

Alam, S., Illo, C., Ma, Y. T., & Punia, P. , "Gemcitabine-induced cardiotoxicity in patients receiving adjuvant chemotherapy for pancreatic cancer: a case series", Case reports in oncology, 2018 Jan .
Alam, S., Illo, C., Ma, Y. T., & Punia, P. , "Gemcitabine-induced cardiotoxicity in patients receiving adjuvant chemotherapy for pancreatic cancer: a case series", Case reports in oncology, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on gemcitabine (the active ingredients of Gemcitabine) and Gemcitabine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.